Figures & data
Table 1. Study of patient demographics in dose escalation of OrienX010.
Table 2. Summary of adverse events and grade in OrienX010 vaccination dose escalation study.
Figure 1. (A) Kaplan–Meier curves for progression free survival and overall survival for the OrienX010 dose escalation trial. The median PFS was 16.3 mo (497 d). Median OS has not been met. (B) Kaplan–Meier curves for progression free survival and overall survival for the DC–CIK therapy expansion trial. The median PFS was 9.9 mo (301 d). Median OS has not been met.
Figure 2. (A) Metastatic melanoma baseline CT of right submandibular (SM) met pre-OrienX010, (B) SM met post-OrienX010, and (C) SM met s/p after three cycles of DC -CIK therapy. (D) Malignant thymoma baseline CT of mediastinal mass (MM) pre-OrienX010, (E) MM after OrienX010, and (F) MM after two cycles of DC -CIK therapy. (G) Metastatic breast cancer baseline CT of left breast (LB) mass before OrienX010, (H) LB mass after OrienX010, and (I) LB mass after one cycle of DC -CIK therapy.
Figure 3. Clone populations in TCR β repertoires. (A) Schema for patient 401 tracks clone populations over time and b/w OrienX010 and DC–CIK treatments: purple clones first appear in the baseline sample, orange in the post-ORIEN sample, green in the pre-DC–CIK, and blue in the post-DC–CIK. (B) Patients 401, 506, 602, 603, and 604 received both OrienX010 and DC–CIK therapy, whereas patients 402, 403, 501, and 504 received OrienX010 only.
